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For the past 20 years, the practice of cardiology has revolved
around the choice between medical therapy and revasculariza-
tion for the treatment of coronary artery disease. Good patient
care requires a thorough history, physical examination and
review of pertinent laboratory data (source data when possi-
ble) before discussing whether medicines or revascularization
would make the patient live longer or feel better, or both.
Decisions regarding quality of life, in particular, require con-
siderable feedback from the patient. Lately, we also ask about
the cost of the therapeutic approach.
In this issue of the Journal, Laouri et al. (1) have assembled
a “nine-member multispecialty national panel of expert physi-
cians and surgeons” and are looking for an invitation to come
on rounds with us, because as the authors state, “as cost-
containment pressures escalate, it is important that safeguards
be established to promote the provision of highly beneficial
care” (1). This is the motivation for their efforts to define the
clinical circumstances where revascularization procedures are
necessary and to develop a method to test whether an individ-
ual patient is receiving necessary care.
Before subscribing to the conclusions of Laouri et al. (1)
about revascularization underuse in six southern California
hospitals, their underuse detection tool should be examined
more carefully. Their current patient cohort was previously
described in a report published in 1995 (2), a study designed to
validate the underuse tool. From 518 clinical scenarios previ-
ously judged to be appropriate indications for revasculariza-
tion, their expert panel rated 248 indications for revasculariza-
tion as necessary (143 for coronary artery bypass graft surgery
[CABG], 36 for percutaneous transluminal coronary angio-
plasty [PTCA] and 69 indications where either CABG or
PTCA would be considered necessary). Necessary means that
“a competent and scrupulous physician would offer it to almost
every patient meeting the criteria” (2). For a procedure to be
considered necessary, 1) the benefits to the patient outweigh
the risk; 2) it would be improper care not to provide the
service; 3) the probability of benefit is not small; and 4) the
magnitude of benefit is not small (1). These are strong terms,
particularly since the RAND group (3) has written that
“malpractice might be suggested if the procedure is withheld.”
Unanimous agreement among the panelists was not re-
quired to designate an indication as necessary, and the RAND
investigators themselves have commented on the considerable
disagreement that they observe among their experts (4). In the
current investigation, because 25% of patients did not receive
necessary revascularization, agreement with expert panel rec-
ommendations was also sought from one of two invasive
cardiologists at the participating hospitals. The implication of
this approach is that both consultants did not agree in all the
cases. Surely, if the practicing community does not agree with
revascularization in 25% of the patients, failure to follow the
indications cannot be malpractice. It is possible that agreement
would have been even lower had a noninvasive cardiologist
been asked for a second opinion (5). Furthermore, the RAND
expert panel disagrees with the American College of
Cardiology/American Heart Association expert panel guide-
lines for revascularization (6,7) and with ongoing National
Heart, Lung, and Blood Institute-sponsored clinical investiga-
tions. The Asymptomatic Cardiac Ischemia Pilot Study is still
recommending randomized trials to assess the relative merits
of revascularization versus medical therapy for many of the
RAND group’s necessary indications for revascularization (8).
The reader is urged to study the examples of necessary
indications given in Table 1 of Laouri et al. (1). Some seem
overly aggressive (see later).
To support the validity of their necessary indications, the
RAND group sampled charts of patients undergoing coronary
angiography, and those patients who were suitable candidates
for revascularization were studied more closely (2). After
reading the abstracted data from these patients, a physician
identified 671 patients who had necessary indications for
coronary revascularization. These 671 patients were the sub-
jects of the previous validation study (2) as well as in the
current report (1) in this issue of the Journal. Mortality was
higher among the 168 patients not receiving revascularization
than in the 503 having the procedures, but several factors
should be considered before accepting the validity of the
necessary criteria as applied to clinical practice: 1) Only 62%
of patients not known to be dead were contacted for follow-up.
This low follow-up rate weakens the study conclusions. 2) The
type of medical therapy administered; adherence to therapy;
intercurrent events; and physician, social and economic sup-
port in the follow-up period were not described. When prac-
ticing physicians followed the panel’s recommendations for
revascularization, the choice of procedure (PTCA vs. CABG)
was at variance with the panel’s recommendation in 19%, and
mortality was not obviously affected by the type of procedure
used. Mortality was highest among patients who had necessary
indications for revascularization and revascularization type not
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specified by the panel but who did not undergo either CABG
or PTCA (23.3% mortality rate). In this uncontrolled setting,
these data could be interpreted to mean that the indications
for revascularization were simply markers for high risk regard-
less of the therapy provided.
If revascularization were to be recommended and properly
performed, how much procedural morbidity is acceptable, and
how much longer or better should a patient live, to merit the
designation of requiring a necessary procedure? For the
RAND population with PTCA necessary indications, unad-
justed mortality was in fact higher for patients undergoing
PTCA than for those with no revascularization. For CABG
indications, after ;800 days of follow-up, the mortality rate
was 10% with the procedure versus 17% without, but the
benefit did not apply equally to all patients with necessary
indications. In the multivariate models, the mortality benefit
from revascularization, as expected, was greatest for patients
with left main coronary artery or multivessel disease, a reduced
left ventricular ejection fraction and unstable or severe angina.
The mortality benefit reached statistical significance only for
patients with markedly impaired ventricular performance (2).
It is well known that the worse the ischemia, particularly
among patients with impaired ventricular performance, the
greater the survival benefit from revascularization compared
with medical therapy (9). The RAND panel recommendations
go beyond these traditional, well tested indications for revas-
cularization. The data presented in these reports (1,2) suggest
that practicing physicians did not view all necessary indications
as equally necessary. For example, left main disease, but not
chronic stable angina, was strongly associated with a patient
undergoing an operation, regardless of the type of hospital.
Somewhat paradoxically, preserved ventricular function was
strongly associated with the performance of necessary PTCA,
or PTCA or CABG when either was deemed a suitable
revascularization technique. Thus, a lower procedural risk
appears to be highly influential in the physician’s perception of
the need to perform a procedure, particularly when there was
not a clear survival advantage offered by the procedure.
What do the patients think of these necessary indications?
The authors state that only 16 of the 168 patients not receiving
revascularization refused their physician’s recommendation
(2). It is unclear whether this relatively small number encom-
passes all the refusals. That is, ascertainment of the true
number of refusals may not have been complete. Furthermore,
during the course of a discussion about the merits of revascu-
larization, the distinction between patient refusal and physi-
cian uncertainty is often blurred. Regardless, for those patients
who stated that they refused revascularization, a statistical
difference in survival was not equivalent to necessity. Medical
survival in patients with preserved ventricular performance is
.80% at 7 years, even though survival with revascularization
might be better for certain subgroups (6,9). A thorough
discussion of the risks, benefits and treatment alternatives
remains a necessary procedure.
Revascularization to improve the quality of life is an even
more difficult indication to classify as necessary. In the cohort
of Laouri et al. (1) revascularization for the relief of chest pain
met with mixed results, reducing the frequency of chest pain
rather than the probability of having any chest pain (2).
For these reasons, I am not enthusiastic about the underuse
tool, in its current form, as an aid in the management of
individual patients with coronary artery disease. What about a
broader use? In this issue of the Journal, Laouri et al. (1) use
the underuse tool to assess the grosser behaviors of hospital
systems. They conclude that revascularization is generally
underused, especially among African-American and public
hospital patients. I am not yet convinced that the observed
differential use is always synonymous with underuse. Tools to
help make this distinction are urgently needed (10). Only six
hospitals were included in the report by Laouri et al. (1).
Generalizing the results to all public and private hospitals is
premature. Physician data including the numbers involved in
patient care, their training, and financial incentives are lacking,
as are resource issues including the location and quality of the
surgical and angioplasty programs. Patient variables of interest
would be illness duration, physician relationship and social and
employment history. As previously noted, the precise number
of patients who refused a recommended procedure is not
clearly stated. Follow-up was not complete. Knowledge of
these variables would help to better explain the reasons for the
observed differences in the use of revascularization.
When the RAND group set out to develop the underuse
tool, they asked whether this technology was merely a more
refined way of recording the conventional wisdom and whether
the tool was valid, worth the investment and ready for wide-
scale implementation (2). From my reading of their method-
ology, a traditional multivariate model that included key
clinical variables, such as the extent of ischemia and ventricular
function, did at least as well as the expert panel in predicting
benefit from revascularization. It is therefore not clear how the
expert panel deliberations add to our understanding of the
necessity of revascularization (2). Despite this reservation,
Laouri et al. (1) suggest that “if criteria for necessary revascu-
larization were placed on hospital computers . . . patients
needing revascularization would be identified more read-
ily . . . alternatively . . . clinicians should provide explicit clini-
cal justification for not doing so.” Having participated in an
investigation of clinical efficacy that relied heavily on expert
panel deliberations (11), I am most appreciative of the major
contribution that the RAND group has made to this most
complex and difficult methodology. However, the method is
still too immature to be considered a clinical standard and
should not be adopted as a fail-safe mechanism against overly
aggressive cost cutting in cardiovascular medicine. The cardi-
ologist at the bedside, in cooperation with local quality im-
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provement efforts, is still the standard of care. Multivariate
models of medical versus surgical outcome are a useful refer-
ence tool (9). After all, when Laouri et al. (1) noted that expert
panel recommendations were not even followed at private
hospitals, they asked local cardiologists to review the cases and
gained considerable comfort from their judgments.
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